Abstract: A drug administration management system according to an embodiment of the present disclosure may include a smart case configured to accommodate a drug administration device, display drug administration information including whether or not a drug is administered and a drug administration dose for each drug administration site input button based on an input of a user, and transmit the drug administration information externally; and a terminal configured to receive the externally transmitted drug administration information from the smart case, and monitor the drug administration information based on a drug administration plan input from a user.

Abstract: An indoor wireless positioning method according to one embodiment of the present invention includes receiving initial received signal strength indicator (RSSI) information from a reception unit; searching for a fingerprint matching measured initial RSSI information in a fingerprint database; determining a first location corresponding to the retrieved fingerprint to be an initial location of the reception unit; receiving additional RSSI information from the reception unit; extracting features of variability between the additional RSSI information and the initial RSSI information; searching for variability fingerprints matching the initial location and extracted RSSI variability features in a variability fingerprint database; and updating a second location to a current location of the reception unit when the second location corresponding to the retrieved variability fingerprint is different from the initial location, wherein the second location is a location in a candidate area within a preset distance range ce

Abstract: A method for synthesizing a pre-hydrolyzed polysilicate, wherein a polysilicate is applied as a reactant when synthesizing the pre-hydrolyzed polysilicate, and the total amount of water added in the reaction system is specified. The method is capable of omitting a condensation reaction by applying a polysilicate as a reactant, thereby significantly shortening synthesis time and reducing production costs when compared with a typical synthesis method in which alkoxysilane-based monomer compound is used as a reactant. In addition, the gelation reaction time and the weight average molecular weight can be easily controlled, and a pre-hydrolyzed polysilicate excellent in storage stability and processability can be synthesized.

Abstract: A sound control device in a vehicle and control method thereof may include obtaining energy per unit time of an audio signal corresponding to a preset low frequency band, calculating an allowable reference value based on a difference between a magnitude of energy per unit time of the audio signal and a magnitude of a preset maximum allowable input of a speaker, monitoring whether a magnitude of energy per unit time of a noise control signal for eliminating noise in the vehicle exceeds the allowable reference value, and adjusting a magnitude of the noise control signal when the magnitude of energy per unit time of the noise control signal exceeds the allowable reference value.

Abstract: Disclosed are a separator for fuel cells capable of minimizing the volume of a system and the use of sealants, and a stack for fuel cells, more particularly, a stack for solid oxide fuel cells, including the same. Specifically, by adding a metal sheet having a specific shape, position and size to the separator, the stress applied to the sealant can be uniformized, and thus the oxidizing agent and fuel can be separated and electrically isolated using only a piece of sealant. Therefore, the stack for fuel cells is characterized in that there is no variation in temperature, reactant concentration, power, or the like between respective unit cells, so delamination and microcracks do not occur, the volume is minimized, and the power density per unit volume is very high.

Abstract: A quantization device includes: a trellis-structured vector quantizer which quantizes a first error vector between an N-dimensional (here, “N” is two or more) subvector and a first predictive vector; and an inter-frame predictor which generates a first predictive vector from the quantized N-dimensional subvector, wherein the inter-frame predictor uses a predictive coefficient comprising an N×N matrix and performs an inter-frame prediction using the quantized N-dimensional subvector of a previous stage.

Abstract: The present invention relates to an siRNA targeting PRK2, which is a hepatitis C virus therapeutic agent, and can be effectively used as a hepatitis C virus therapeutic agent since the systemic delivery into a living body, particularly liver cells, is possible through an siRNA targeting a host PRK2 gene, which shows an anti-HCV activity, or a lipid formulation thereof.

Abstract: The present invention relates to an siRNA targeting PRK2, which is a hepatitis C virus therapeutic agent, and can be effectively used as a hepatitis C virus therapeutic agent since the systemic delivery into a living body, particularly liver cells, is possible through an siRNA targeting a host PRK2 gene, which shows an anti-HCV activity, or a lipid formulation thereof.

Abstract: The present invention relates a novel composition for preventing or treating hepatitis C virus, regulating the phosphorylation of a replicase. More specifically, it is possible to prevent or treat hepatitis C using a novel PRK2 inhibitor discovered through structure modeling, and to prevent or treat hepatitis C, particularly, interferon-insensitive hepatitis C through coadministration of an Hsp90 inhibitor.

Abstract: The present invention relates a novel composition for preventing or treating hepatitis C virus, regulating the phosphorylation of a replicase. More specifically, it is possible to prevent or treat hepatitis C using a novel PRK2 inhibitor discovered through structure modeling, and to prevent or treat hepatitis C, particularly, interferon-insensitive hepatitis C through coadministration of an Hsp90 inhibitor.

Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.

Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.